BOD Science has released the results of its second pharmacokinetic study for Aqua Phase, the technology that acts as a drug delivery system that can make water-hating (or lipophilic) drugs, such as cannabinoids (CBD) water-soluble.
The most recent study, which completes Bod Science's research and development work, demonstrated that Aqua Phase delivers six times greater bioavailability in comparison to CBD in oil, as well as triple the maximum concentration levels.
It also showed that Aqua Phase is faster-acting, reaching its maximum concentration in two and a half hours versus six hours for CBD in oil.
"In particular, the enhanced tolerability of Aqua Phase has the potential to improve the experience of patients who can't tolerate the oils used in most CBD products.
"Excessive oil consumption can cause various digestive symptoms such as nausea and indigestion," said Janet Wilson, Head of R&D at Bod.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Nov 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Nov 23
